Table 1. Demographic and clinical characteristics.
| Variables |
Healthy controls (n=28)
|
Ultrahigh risk (n=24)
|
Schizophrenia (n=21)
|
Analysis | df | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | s.d. | Mean | s.d. | Mean | s.d. | F or χ 2 | |||
| Age (yrs) | 23.64 | 4.09 | 21.29 | 3.1 | 23.67 | 4.33 | 3 | 2 | |
| Gender (m/f) | 18/10 |
18/6 |
16/5 |
0.58 | 2 | ||||
| Education (yrs) | 14.36 | 1.47 | 13.21 | 1.82 | 13.48 | 2.6 | 2.45 | 2 | |
| IQ | 111.36 | 15.42 | 108.88 | 14.5 | 100.91 | 9.4 | 3.70a | 2 | |
| Parental SES | 2.89 | 0.88 | 3.17 | 1.17 | 2.62 | 0.74 | 1.87 | 2 | |
| PANSS | 58.38 | 12.48 | 54.29 | 12.03 | 1.24 | ||||
| CAARMS | 40.52 | 14.4 | |||||||
| GAF | 90.93 | 3.36 | 53.9 | 6.96 | 60.76 | 11.3 | 178.92a | 2 | |
| HAMA | |||||||||
| HAMD | |||||||||
| CPZ doses (mg/day) | 151.92 | 215.28 | 392.21 | 199.38 | |||||
| Neuroleptic medication (AP/AD/both/none) | (3/0/1/20) | (13/0/7/1) | |||||||
Abbreviations: AD, antidepressant; AP, antipsychotics; CAARMS, comprehensive assessment of at-risk mental states; CPZ, Chlorpromazine equivalent dose; df, degrees of freedom; f, female; GAF, Global Assessment of Functioning; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; IQ, Intelligence Quotient; m, male; PANSS, Positive and Negative Syndrome Scale; SES, Socioeconomc Status; yrs, years.
χ 2 analysis for categorical data.
a P<0.05.